Close
Close
People News

Aduro Biotech Announces Management Changes

3.16666666667
3.2 from 6 votes
Friday, January 05, 2018

BERKELEY, Calif. - Aduro Biotech, Inc. (NASDAQ:ADRO) a biopharmaceutical company with three distinct immunotherapy technologies, announced that Jennifer Lew has been promoted to chief financial officer. Ms. Lew, who previously served as the company's senior vice president of finance, will oversee the company's global finance operations, including accounting, planning, and investor relations functions. Separately, Gregory W. Schafer will be stepping down from his position as chief operating officer in early March and has agreed to continue as a consultant to the company to facilitate a smooth transition of responsibilities.

"I am very pleased to congratulate Jen, an important and valued leader in the organization, on a well-deserved promotion," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "Jen has played an integral role at Aduro, including participating in the company's 2015 initial public offering and in maintaining the company's strong cash position."

Steve continued, "I want to thank Greg for his tremendous contributions in the growth and development of Aduro these last four years. His expertise and leadership were essential to securing key partnerships and building the robust pipeline we have today."

Jennifer Lew
Jennifer Lew joined Aduro in October 2013 and has served as our Senior Vice President of Finance since January 2015. Prior to joining Aduro, from 2004 to 2013, Ms. Lew held various positions of increasing responsibility at Dynavax Technologies, culminating as Vice President of Finance and Principal Accounting Officer responsible for all accounting and finance operations. Earlier in her career Ms. Lew served as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Ms. Lew earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro's B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. Aduro's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient's tumor. Other Listeria strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

 

Source: Aduro Biotech
3.16666666667
3.2 from 6 votes
Free Newsletter
Trending News
Videos
by Scott Harwood
6 views
by Abidemi Uruejoma
11 views
by Scott Harwood
12 views
by Scott Harwood
11 views
by Abidemi Uruejoma
39 views